(BMEA) – Hot FDA News
-
Biomea Fusion, Inc. (BMEA) Announces BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
-
Biomea Fusion (BMEA) Presents Positive Clinical Data from Initial Cohorts of Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus
-
Back to BMEA Stock Lookup
